Kinetics of Ig therapy discontinuation and overall survival in the 2 study groups. (A) Three-year cumulative incidence of discontinuation of IVIg replacement therapy in the MMRDT and UCBT groups. (B) Probability of 5-year OS for SCID patients according to the use of MMRDT or UCBT.